Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $61.8 billion by ...

The U.S. Court of Appeals on Wednesday stayed an order that would bar Regeneron Pharmaceuticals and Sanofi from selling their cholesterol drug Praluent.The drugmakers can continue to sell the ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Regeneron Pharmaceuticals and Sanofi will lower the price of their cholesterol drug Praluent by up to $9,500 annually for Express Scripts customers. In return, Express Scripts will grant the ...

Paris – April 6, 2020 – Sanofi has finalized the planned restructuring related to Praluent ® (alirocumab) with Regeneron Pharmaceuticals, Inc. Effective April 1, 2020, Sanofi will have sole ...

Regeneron and Sanofi's licensing deal splits profit from Praluent in the U.S. equally between the two companies, and it also requires splitting profit from overseas sales on a sliding scale that ...